Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection-Reference-Cited by-同舟云学术

Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection

Published:2019-08 Issue:15 Volume:29 Page:1874-1880
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Shah Khushbu,Queener Sherry,Cody Vivian,Pace Jim,Gangjee Aleem^ORCID

Funder

National Institute of Allergy and Infectious Diseases

Duquesne University

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference38 articles.

1. Pneumocystis jirovecii—from a commensal to pathogen: clinical and diagnostic review;Sokulska;Parasit Res,2015

2. Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control;Yiannakis;J Hospital Infection,2016

3. Truong J, Ashurst JV. Pneumonia, Pneumocystis (Carinii) Jiroveci. [Updated 2018 Feb 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482370/.

4. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid;Chew;J Clin Rheumatol Practical Rep Rheumatic Musculoskeletal Dis,2015

5. Human immunodeficiency virus and fungal infections;Guarner;Semin Diagn Pathol,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facile Synthesis of 2-Substituted Quinazolines via Ruthenium(II)-Catalyzed Acceptorless Dehydrogenative Coupling;Current Organic Chemistry;2024-02

2. SnAr Reactions of 2,4-Diazidopyrido[3,2-d]pyrimidine and Azide-Tetrazole Equilibrium Studies of the Obtained 5-Substituted Tetrazolo[1,5-a]pyrido[2,3-e]pyrimidines;Molecules;2022-11-08

3. Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021);Expert Opinion on Therapeutic Patents;2022-10-03

4. Synthetic strategies for anticancer antifolates;New Strategies Targeting Cancer Metabolism;2022

5. An Insight into Synthetic Strategies and Recent Developments of Dihydrofolate Reductase Inhibitors;ChemistrySelect;2021-11-18